These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 18270154)
1. Management of drug resistance in the population: influenza as a case study. Moghadas SM Proc Biol Sci; 2008 May; 275(1639):1163-9. PubMed ID: 18270154 [TBL] [Abstract][Full Text] [Related]
2. A comparative evaluation of modelling strategies for the effect of treatment and host interactions on the spread of drug resistance. Alexander ME; Dietrich SM; Hua Y; Moghadas SM J Theor Biol; 2009 Jul; 259(2):253-63. PubMed ID: 19344730 [TBL] [Abstract][Full Text] [Related]
3. Antiviral resistance and the control of pandemic influenza. Lipsitch M; Cohen T; Murray M; Levin BR PLoS Med; 2007 Jan; 4(1):e15. PubMed ID: 17253900 [TBL] [Abstract][Full Text] [Related]
4. Antiviral resistance during pandemic influenza: implications for stockpiling and drug use. Arino J; Bowman CS; Moghadas SM BMC Infect Dis; 2009 Jan; 9():8. PubMed ID: 19161634 [TBL] [Abstract][Full Text] [Related]
5. Antiviral prophylaxis during pandemic influenza may increase drug resistance. Eichner M; Schwehm M; Duerr HP; Witschi M; Koch D; Brockmann SO; Vidondo B BMC Infect Dis; 2009 Jan; 9():4. PubMed ID: 19154598 [TBL] [Abstract][Full Text] [Related]
6. Emergence of drug-resistant influenza virus: population dynamical considerations. Regoes RR; Bonhoeffer S Science; 2006 Apr; 312(5772):389-91. PubMed ID: 16627735 [TBL] [Abstract][Full Text] [Related]
7. Optimality of a time-dependent treatment profile during an epidemic. Jaberi-Douraki M; Moghadas SM J Biol Dyn; 2013; 7(1):133-47. PubMed ID: 23859002 [TBL] [Abstract][Full Text] [Related]
8. Optimizing treatment regimes to hinder antiviral resistance in influenza across time scales. Patterson-Lomba O; Althouse BM; Goerg GM; Hébert-Dufresne L PLoS One; 2013; 8(3):e59529. PubMed ID: 23555694 [TBL] [Abstract][Full Text] [Related]
9. Intervention strategies for an influenza pandemic taking into account secondary bacterial infections. Handel A; Longini IM; Antia R Epidemics; 2009 Sep; 1(3):185-95. PubMed ID: 20161493 [TBL] [Abstract][Full Text] [Related]
10. Modeling the effects of drug resistant influenza virus in a pandemic. Brockmann SO; Schwehm M; Duerr HP; Witschi M; Koch D; Vidondo B; Eichner M Virol J; 2008 Oct; 5():133. PubMed ID: 18973656 [TBL] [Abstract][Full Text] [Related]
11. Influenza virus resistance to antiviral therapy. van der Vries E; Schutten M; Fraaij P; Boucher C; Osterhaus A Adv Pharmacol; 2013; 67():217-46. PubMed ID: 23886002 [TBL] [Abstract][Full Text] [Related]
13. Neuraminidase inhibitor resistance in influenza: assessing the danger of its generation and spread. Handel A; Longini IM; Antia R PLoS Comput Biol; 2007 Dec; 3(12):e240. PubMed ID: 18069885 [TBL] [Abstract][Full Text] [Related]
14. Impact of emerging antiviral drug resistance on influenza containment and spread: influence of subclinical infection and strategic use of a stockpile containing one or two drugs. McCaw JM; Wood JG; McCaw CT; McVernon J PLoS One; 2008 Jun; 3(6):e2362. PubMed ID: 18523549 [TBL] [Abstract][Full Text] [Related]
15. [High prevalence of antiviral resistant influenza, and reduced clinical effectiveness of the antivirals against resistant influenza strains]. Saito R Jpn J Antibiot; 2010 Feb; 63(1):81-91. PubMed ID: 20836406 [No Abstract] [Full Text] [Related]